Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

8.09
+0.51006.73%
Post-market: 8.110.0209+0.26%19:58 EDT
Volume:7.21M
Turnover:58.70M
Market Cap:837.99M
PE:-1.55
High:8.40
Open:7.79
Low:7.75
Close:7.58
Loading ...

Intellia Therapeutics Price Target Maintained With a $10.00/Share by Wedbush

Dow Jones
·
19 May

Sector Update: Health Care Stocks Steady-to-Lower Pre-Bell Monday

MT Newswires Live
·
19 May

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday After Moody's Downgrades US Credit Rating

MT Newswires Live
·
19 May

Top Premarket Gainers

MT Newswires Live
·
19 May

TD Cowen Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
19 May

Intellia Therapeutics Reports Positive Phase 1 Trial Results

TIPRANKS
·
19 May

Intellia Therapeutics: Promising Early Data on Nex-Z Met with Caution Due to Small Sample Size and Need for Further Trials

TIPRANKS
·
19 May

Intellia Therapeutics Says Drug Shows Potential in Phase 1 Transthyretin Amyloidosis Trial

MT Newswires Live
·
19 May

Intellia Therapeutics announces two-year follow-up data from trial of nex-z

TIPRANKS
·
18 May

Intellia Announces Positive Two-Year Follow-up Data From Ongoing Phase 1 Study of Nexiguran Ziclumeran (Nex-Z), in Patients With Hereditary Transthyretin (Attr) Amyloidosis With Polyneuropathy at Peripheral Nerve Society Annual Meeting

THOMSON REUTERS
·
18 May

Truist Financial Keeps Their Buy Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
13 May

Stock Track | Intellia Therapeutics Soars 7.70% Pre-Market Following Evercore ISI's Buy Rating Reiteration

Stock Track
·
12 May

Stock Track | Intellia Therapeutics Soars 7.70% in Pre-Market Following Evercore ISI's Buy Rating Reiteration

Stock Track
·
12 May

Intellia Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
12 May

Evercore ISI Remains a Buy on Intellia Therapeutics (NTLA)

TIPRANKS
·
12 May

Stock Track | Intellia Therapeutics Soars 5.07% Pre-Market on Positive Analyst Ratings

Stock Track
·
09 May

RBC Trims Price Target on Intellia Therapeutics to $30 From $32, Keeps Outperform, Speculative Risk

MT Newswires Live
·
09 May

Intellia Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
09 May

Intellia Therapeutics price target lowered to $10 from $14 at Citi

TIPRANKS
·
09 May

Bank of America Securities Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
09 May